Keytruda

Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings

Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda

|

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

|

Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline

|

Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut

|

Keytruda Recent News

What Drove Merck's Keytruda Shortfall In Q4

|

What's Behind PDS Biotech's Rally?

|

Merck's Keytruda Gets A Double Dose Of Positive News

|

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

|

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

|

Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward

|

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

|

Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

|

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

|

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

|

Merck Is Up 40% In 2018: What's Driving The Rally?

|

Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

|

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

|

Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

|

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

|

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

|

Early Keytruda Results Win Merck An Upgrade

|

The Bull Thesis For Merck Is Evaporating

|

Analyst Grows Cautious On Merck's Keytruda

|

Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

|

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

|

Tracking The Busy June PDUFA Calendar

|

The Most Notable Abstracts Released Ahead Of ASCO 2017

|